By Sam Boughedda
On Friday, it was announced that Bristol-Myers Squibb (NYSE: BMY ) will acquire Turning Point Therapeutics (NASDAQ: TPTX ) for $4.1 billion or $76 a share, more than double Thursday's closing price of $34.16.
Following the news, Stifel analyst Bradley Canino said the cash offer for TPTX is "a fair offer," valuing TPTX’s pipeline at $3.2 billion.
"This offer price is double the current stock price and our valuation for the company, and it will surprise many investors that over the past year that have begun to believe late-to-market targeted oncology drugs are likely to be commercial failures—even those with clinical data differentiation, like repotrectinib. More broadly, this is a needed validation of the targeted oncology space," said Canino.
"It suggests both that value can still be extracted from incremental improvements on known and approved drug mechanisms, and that large pharma is ready to fill its late-stage pipelines and launch drugs with such profiles."
Meanwhile, BMO's Evan David Seigerman said in a note to clients that "while Bristol was not on list of companies that need to buy, this potential acquisition could help bolster the company's offering in NSCLC."
"TPTX's portfolio includes other early stage clinical assets across targeted oncology. We see this deal as a positive for the sector and could signal an increased willingness to transact among BioPharma."
Add Chart to Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
- Enrich the conversation
- Stay focused and on track. Only post material that’s relevant to the topic being discussed.
- Be respectful. Even negative opinions can be framed positively and diplomatically.
- Use standard writing style. Include punctuation and upper and lower cases.
- NOTE: Spam and/or promotional messages and links within a comment will be removed
- Avoid profanity, slander or personal attacks directed at an author or another user.
- Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
- Only English comments will be allowed.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.